Pharmacological action of the drug
A homeopathic remedy that relieves a complex of somatic and mental symptoms characteristic of the pre-, peri- and postmenopausal period. It has an estrogen-like effect, affecting the hypothalamus-pituitary gland-ovaries , which causes a decrease in the secretory function of the anterior pituitary gland , which produces luteinizing hormone .
A decrease in the production of gonadotropins ensures the elimination of vegetative-vascular disorders ( nervous excitability , headache , hot flashes , tachycardia , dizziness ) and psycho-emotional conditions that develop against the background of a simultaneous sharp decrease in estrogen and an increase in the secretion of luteinizing and follicle-stimulating hormones .
Klimaktoplan in the treatment of menopausal syndrome
About the article
10086
0
Regular issues of "RMZh" No. 1 dated January 14, 2005 p. 11
Category: General articles
Authors: Baranov I.I. , Serov V.N. 1 1 Russian Society of Obstetricians and Gynecologists, Moscow, Russia
For quotation:
Baranov I.I., Serov V.N. Climactoplan in the treatment of menopausal syndrome. RMJ. 2005;1:11.
Currently, there is a clear trend towards increasing life expectancy of the population. According to WHO forecasts, by 2015, 46% of women are expected to be over 45 years of age. The study of issues related to aging occupies one of the leading places in modern medicine. Aging is a natural and inevitable process. A certain milestone in the involution of both the female and male body is the loss of reproductive function, which leads to a number of pathological changes in various organs and systems.
The age at which menopause occurs remains fairly stable and is about 50 years in various regions of Russia. Consequently, a woman spends more than a third of her life in a state of deficiency of female sex hormones. The onset of menopause is one of the critical periods in a woman’s life. It is in the peri- and postmenopausal period that a number of somatic and mental diseases appear, which significantly affect the quality and overall life expectancy. In 65–80% of women, as a result of physiological estrogen deficiency, which occurs several years before menopause and then worsens as the ovaries atrophy, menopausal syndrome develops. Severe menopausal disorders occur in approximately 30–40% of cases. Differences in the range of clinical manifestations and their severity are to some extent explained by the constitutional characteristics of the density of distribution of estrogen receptors in organs and tissues. In addition, the development of menopausal complications is influenced by unfavorable external factors, the presence of concomitant chronic pathology, etc. The physiological shutdown of reproductive function is associated with a restructuring of the hypothalamus and pituitary gland. At the same time, the level and cyclicity of production of gonadotropic hormones - follicle-stimulating hormone (FSH) and luteinizing hormone (LH) - changes. Stimulation of the ovaries decreases, the production of estradiol in the ovarian follicles decreases. Ovulation does not occur, the corpus luteum is not formed, and accordingly, progesterone is not formed. A decrease in the level of estrogen secretion is also associated with age-related changes in the content of primordial follicles in the ovaries, which become smaller. In conditions of deficiency of ovarian hormones, compensatory and adaptive mechanisms develop. The adrenal glands play a leading role in this. They begin to produce an increased amount of androgens - male sex hormones, which, in turn, turn into estrogens through their conversion (aromatization) in subcutaneous fat tissue. In this case, mainly estrone is formed, which is inferior in the strength of its biological effect to estradiol. However, if a woman does not have hidden or obvious adrenal insufficiency, estrone is quite enough to easily endure the menopause. The source of discomfort in women is dysfunction of the hypothalamic-pituitary system. Violation of autonomic regulation on the part of the hypothalamus provokes increased sweating, dizziness, nausea and hot flashes. For the most part, these reactions are vascular, capillary in nature. An increase in prolactin production by the pituitary gland often accompanies menopausal syndrome. Due to the high content of prolactin in the blood, the secretion of estrogen by the ovaries is further inhibited. In addition, prolactin enhances proliferative processes in the mammary glands and uterus. As a result, the risk of uterine fibroids and mastopathy increases significantly. As for neurotic reactions, such as increased irritability, nervousness, tearfulness, sleep disturbance, suicidal thoughts, their reason lies not only in somatic disorders, but also in the highly psychotraumatic nature of the situation. The first description of menopausal symptoms dates back to 1776, the term “menopause” appeared in France, and was first used in medical literature in 1821. Regis de Bordeaux was the first to use ovarian extract to treat women with “madness induced by castration” in 1893. In modern society, characterized by a change in the demographic situation towards an increase in the older age group, the problem of timely correction and prevention of menopausal disorders in the peri- and postmenopausal period in women is of particular relevance. The most common phenomena accompanying age-related insufficiency of female sex hormones include disorders of the autonomic nervous system, atrophic changes in the vaginal wall, skin and mucous membranes, resulting in urogenital chronic inflammatory diseases, dermatitis, etc. It has been proven that in 75% of cases, the development of postmenopausal osteoporosis, which is the cause of severe disabling injuries (fracture of the femoral neck, vertebral bodies, etc.), is associated precisely with a lack of estrogens, which are directly involved in the remodeling of bone tissue and inhibit its resorption. Metabolic disorders leading to the development of cardiovascular and endocrine pathologies are especially dangerous for the health and life of women. Hypercholesterolemia, dyslipidemia, insulin resistance, as a consequence of hyperandrogenization of the female body, as well as abdominal obesity are the main components of the metabolic syndrome, which is associated with arterial hypertension, atherosclerosis, and diabetes mellitus. Serious complications of the latter are heart attack and stroke, often leading to disability or death. Not the last place in the pathology of menopause is occupied by emotional disorders. This is due to the fact that estrogens play a role in the normal functioning of neurotransmitter systems responsible for the formation of emotions. Affective disorders (depression, anxiety) aggravate the course of menopausal syndrome, significantly reduce social functioning, and negatively affect a woman’s quality of life. Many women approach menopause with existing diseases of the endocrine system. The comorbidity of menopausal syndrome and diseases of the endocrine system creates conditions for possible mutual aggravation, masking the clinical manifestations of diseases or changing the course of the underlying endocrine disease, both in itself and during treatment. It is known that before menopause, women are less likely to suffer from cardiovascular diseases (CVD) compared to men. With age, the incidence of CVD in women and men becomes equal and then exceeds that in men. In postmenopausal women, CVD is the leading cause of death in women in the United States and other developed countries. Every second woman dies from ischemic heart disease or stroke, while breast cancer kills 1 in 25 women. In Russia, the mortality rate from CVD in women is 63%. In addition, by the age of 70, 40% of women have at least one fracture due to osteoporosis. 50% of women aged 55–60 years suffer from urogenital disorders. Classic risk factors for the development of CVD for both men and women include smoking, arterial hypertension, dyslipidemia, diabetes mellitus (DM), obesity, a sedentary lifestyle, and unhealthy diet. Among endocrine diseases, diabetes ranks first in terms of prevalence, severity of complications and causes of mortality. DM not only assimilates the above risk factors, but has its own specific risk factors for atherogenesis, which include hyperglycemia and insulin resistance. The presence of diabetes increases the risk of developing CVD by 2–4 times. The mortality rate of patients with diabetes after myocardial infarction is 2–3 times higher than that of people without diabetes. Diabetes and menopause are mutually aggravating conditions for the development of atherosclerosis and CVD. The time of menopause and the course of the postmenopausal period in women with diabetes has its own characteristics. Perhaps early menopause is a complication of diabetes. Diabetes eliminates the protection against CVD that is characteristic of women before menopause. Premature menopause increases the already increased risk of CVD. However, in a large percentage of cases, CVD can be prevented by actively controlling risk factors. Menopause is attributed to symptoms affecting most body systems, and its most manifest clinical manifestations are united under the concept of “climacteric syndrome” (CS). In foreign literature it corresponds to “menopausal syndrome”, which includes vasomotor and psycho-emotional disorders. Almost half of women have severe CS, and every third has a moderate course. A milder and shorter course of CS occurs, as a rule, in practically healthy women, while in patients with chronic somatic diseases and psychosomatic disorders, CS proceeds atypically and tends to be prolonged. Vegetoneurotic manifestations most often have the nature of crises, significantly disrupting the general health of a woman for a long time, and sometimes cause emergency hospitalization. Currently, more and more attention is being paid to studying the relationship between the level of sex steroid hormones and the state of the psyche and cognitive functions. Cognitive functions are the processes and activities involved in acquiring and retaining knowledge. Estrogens are known to increase cerebral circulation in postmenopausal women. Moreover, both estrogen and progesterone receptors are present in brain tissue. There is evidence that estrogens can prevent the development of Alzheimer's-like dementia. Thus, against the background of a decrease and “switching off” of ovarian function, a whole range of disorders arises. Therefore, women with symptoms of estrogen deficiency more often turn to a gynecologist, cardiologist, neurologist, psychiatrist, and urologist. In this regard, there is a need to harmonize unified tactics for the management of patients with menopausal disorders. There are several areas that need to be implemented in the treatment of menopausal syndrome: normalization of the function of the hypothalamus, elimination of hormonal imbalances, elimination of vascular disorders, reduction and stabilization of blood pressure, sedative (calming) therapy, treatment of concomitant diseases and syndromes. Today, modern medicine has a fairly wide selection of good drugs for the treatment of menopausal syndrome, experience in the use of these drugs, indicating a noticeable predominance of benefits over the risks of therapy, good diagnostic capabilities, which allows monitoring both positive and negative effects of treatment. It is important to remember that the treatment of menopausal syndrome is not prolongation of life, but improvement of its quality, which may decrease under the influence of the adverse consequences of estrogen deficiency. And a timely solution to the problems of menopause is a real path to good health and well-being, maintaining working capacity and improving the quality of life of an ever-increasing number of women entering this “autumn” period. A promising direction of such treatment and prophylactic work is the comprehensive correction of hormone deficiency conditions based on hormone replacement therapy (HRT). However, despite the fact that the benefits of HRT can be considered proven, the number of postmenopausal women receiving estrogens is small. When prescribing drugs for HRT, a thorough clinical, instrumental and laboratory examination is required: examination by a gynecologist and cytological examination, ultrasound of the pelvic organs, mammography, biochemical blood test are mandatory. The main goal of treating menopausal syndrome without the use of HRT is to achieve therapeutic and preventive effects that are not accompanied by cancer risk and adverse reactions. Currently, selective estrogen receptor modulators, as well as phytoestrogenic drugs, are widely used. Of the phytoestrogens, the most commonly used are preparations containing black cohosh (Actea racemoza). Phytoestrogens - isoflavones and lignans (contained in black cohosh) have a cardioprotective effect, reduce the stiffness of the aortic wall in postmenopausal women, and can prevent the development of atherosclerosis. Black cohosh extract is a phytoestrogenic selective modulator of estrogen receptors, when interacting with genes regulated by estrogen, it has a selective estrogen-like effect on certain organs. The structure of phytoestrogens is similar to tamoxifen, which is prescribed for the treatment and prevention of breast cancer. The estrogenic effect of black cohosh is less pronounced than that of estradiol and diethylstilbestrol, but the degree of dissociation of the latter on estrogen receptors is 100–10,000 times higher. The complex homeopathic preparation Klimaktoplan, which contains not only black cohosh, but also an optimal combination of other components: Sepia, Ignatia, Sanguinaria, has phytoestrogenic properties. A complex of several components with different mechanisms of action leads to a synergistic effect in the treatment of somatic and mental disorders characteristic of menopausal syndrome. It should be noted that Klimaktoplan is registered in dozens of countries around the world and has been used in clinical practice for many years with great success. The effectiveness of the drug has been proven by numerous clinical studies conducted in various countries around the world. The first conclusions regarding the effectiveness and tolerability of the drug Klimaktoplan were made based on the results of an open clinical study of 31 patients with moderate and severe climacteric syndrome. The study included pre- and postmenopausal women aged 46 to 59 years. They received Klimaktoplan 2 tablets 3 times a day for 4–12 weeks. During the 12-week treatment with Klimaktoplan, a decrease in the Kupperman index (below 15 points) was noted, which indicated the effectiveness of therapy. Positive results were achieved in relation to symptoms such as hot flashes, chills, neurovegetative manifestations, as well as in reducing the severity of depressive conditions and, in particular, sleep disorders. In general, the drug was well tolerated by all patients; no side effects were recorded. The effectiveness of Klimaktoplan was confirmed in a multicenter clinical study, which included 172 pre- and postmenopausal patients aged 40 to 60 years. Women noted complaints typical of menopausal syndrome. Klimaktoplan was prescribed 2 tablets 3 times a day for 4 weeks, then 1 tablet 3 times a day for the next 4 weeks. After a course of therapy with Klimaktoplan, the severity of these symptoms decreased by 40–60%. In 80% of women, there was a significant decrease in the frequency of hot flashes, headaches, palpitations, and increased sweating. Analysis of the proliferation of the vaginal epithelium after 8 weeks of therapy showed its slow recovery. This correlates with changes in hormone levels, which confirms the positive effect of the drug on hormonal status. There was a tendency towards an increase in estrogen levels, a decrease in FSH content, and the concentration of progesterone remained unchanged. The patients tolerated the drug well, only 11 of them (6.4%) experienced transient minor side effects at the beginning of therapy, which were regarded as a reaction of primary deterioration to the drug (response to treatment), which did not require discontinuation of the drug. The open international multicenter clinical study involved 1,250 women from different countries (688 in Germany, Switzerland and Austria, 51 in Italy, 111 in Spain, 200 in Russia and 200 in Ukraine). Klimaktoplan was used in the treatment of menopausal disorders in women in the pre-, peri- and early postmenopausal phases. Patients received 2 tablets 3 times a day, after 12 weeks - a maintenance dose (2 tablets 2 times a day). The duration of treatment is 16 weeks. Already the first 12 weeks of treatment were characterized by a high level of remission regarding 25 symptoms of menopausal disorders. Positive dynamics were observed in relation to symptoms such as hot flashes and hyperhidrosis - in 87% of cases; for disorders of the cardiovascular system, sleep and psycho-emotional disorders - in more than 70% of cases, a decrease in the total assessment of symptoms occurred in 985 cases (78.8%). The total symptom score remained unchanged in 0.6% and increased in 3.8% of cases. The results were convincing (70%) with weight loss, headaches and emotional lability, as well as in the presence of rheumatic diseases. It was noted that during treatment with Klimaktoplan, tearfulness, sleep disturbances, fatigue, the number of fainting episodes, hyperhidrosis, headaches, cardiocirculatory disorders, and dry skin disappear or sharply decrease. It has been established that Klimaktoplan can be considered the drug of choice for the non-hormonal treatment of menopausal syndrome. Treatment with this drug is especially indicated for patients who have contraindications to the prescription of hormonal drugs or who refuse such treatment. Data on the therapeutic effect provided by attending physicians and patients were generally consistent: in 80% of cases, these manifestations decreased or disappeared. It should be emphasized that the improvement of the condition in women who previously accepted the HRT occurred in 70.9% of cases that did not receive such treatment - 84.7%, in used phytopreparations - 86.3% or psychotropic drugs - 88.5%. The tolerance of the menopause is recognized in more than 90% of cases of good or very good. In recent years, comparative studies of the treatment of menopause with hormonal and non -hormonal drugs have been conducted. In particular, for 12 months of 1999, the RSMU studied the effect of hormonal and complex homeopathic preparations (menoplantoplane, Edas - 101) on the course of menopause in 123 women during pre- and postmenopause. Along with general clinical methods, when examining patients, they used: calculation of a modified menopausal index, Lusher test, Hamilton scale. As a result of studies, it was found that both types of therapy effectively affect neuro -vegetative symptoms of menopause, and hormonal drugs have a predominant effect on metabolic/endocrine disorders. Complex homeopathic preparations have more influenced psychoemotional disorders, including depressive disorders, did not cause adverse reactions and had no contraindications. In 1999–2000, on the basis of the Scientific Center for Obstetrics, Gynecology and Perinatology of the RAMS, a comparative study of the influence of therapeutic correction of psycho -vegetative disorders in 65 women in postmenopause was carried out for 6–60 years for 6 months. It was established that the menoportoplane effectively stopped psycho -emotional and neurovegetative disorders: all the indicators of the modified Magneperman index, manifestations of autonomic dystonia and hyperventilation syndrome, improved the characteristics of sleep, have significantly reduced, the number of women suffering from headaches has decreased. In 1998, 30 patients with pronounced neurovegetative symptoms of climacteric syndrome took part in a study on the basis of the National Medical University of Ukraine. The diagnosis is established on the basis of general clinical and instrumental research methods (ECG, EEG, REG). After treatment with a climate plane (2 tablets 3 times a day), the frequency of the following symptoms decreased: the tearfulness - 98%, sleep disturbance, fatigue - 96%, constipation - 97%, tides - 95%, dizziness - 93%, hyperhidrosis - 84%, head Pain - 80%, cardiovascular disorders - 78%, dry skin - 65%. The effect of taking the drug was manifested already at the 2nd week, and the maximum efficiency was after 16 weeks. The menopause also found the use of uterine fibroids in the complex therapy. Synthetic agonists of gonadotropin -releasing -hormones that are used for this pathology expressly inhibit the secretion of gonadotropins, which leads to the onset of pharmacological menopause. In such a situation, a severe pharmacogenic hypoestrogen state causes undesirable side effects similar to manifestations of menopause. The climate plane in complex therapy with vitamins and sedatives significantly reduced these phenomena. Given the long -term practical experience of using the Climatoplan in different countries of the world, the data of clinical studies confirming its effectiveness and safety, the drug can be recommended both as monotherapy and included in the comprehensive therapy of menopause in women.
Content is licensed under a Creative Commons Attribution 4.0 International License.
Share the article on social networks
Recommend the article to your colleagues
Pharmacodynamics and pharmacokinetics
The active ingredients have a complex effect on the body:
- Cimicifuga acts on the hypothalamus , reducing nervous agitation, depression and hot flashes.
- Sepia normalizes the endocrine function of the pituitary gland, adrenal cortex and ovaries, thereby relieving headaches and reducing sweating.
- Ignatia normalizes the mental state, relieves general weakness, excessive sweating, headaches and hot flashes.
- Sanguinaria is effective for attacks of fever migraine -type headaches .
- Lachesis has a positive effect on vasomotor disorders and nervous disorders, relieves feelings of internal anxiety and insomnia.
Klimaktoplan N
Klimaktoplan N is a German homeopathic medicine used to alleviate the symptoms of menopausal syndrome. Recent years have been marked by an active search for new drugs for the treatment of menopausal disorders. The desire to preserve women's full lives during menopause has led to the creation of a whole group of hormonal drugs for replacement therapy, which can neutralize many of the consequences of menopause. However, not all women can take hormones: the presence of a number of direct contraindications and adverse reactions in the latter significantly reduces the availability of hormonal therapy. At the same time, many women have an extremely negative attitude towards the use of hormones, and the opinion of a specialist is not always decisive here. In such cases, a reasonable alternative is to abandon hormones in favor of drugs from other pharmacological groups. One of these medicines is Klimaktoplan N. The drug contains five plant and animal components that potentiate and complement each other’s effects. Klimaktoplan N has a fifty-year history of successful use in Western Europe. Today it is also available to Russian consumers. Menopause is a physiological process that is the result of hormonal changes during the menopausal period and is manifested by increased irritability, somnological disorders, headaches, changes in blood pressure, heart rhythm disturbances, hyperhidrosis, and hot flashes. Thanks to a thoughtful combination of active ingredients, Klimaktoplan N suppresses the manifestations of menopausal syndrome and improves the quality of life of a woman during this difficult period. Each ingredient of the drug is worthy of special mention. Black crow (Cimicifuga) acts similarly to the female sex hormones estrogen. It effectively copes with hot flashes, depression, cardialgia, rapid heartbeat, and establishes proper interaction in the hypothalamus-pituitary-ovary chain.
Cuttlefish (Sepia) has a therapeutic effect on impaired function of the adrenal cortex, helps withstand psycho-emotional overload, improves mood, relieves fatigue, increases exercise tolerance, eliminates venous stasis, hyperhidrosis and headaches. Ignatia improves the overall psychological background, improves mood, and dispels excessive worry and anxiety. Canadian blood root (Sanguinaria) is effective for migraine pain, hot flashes, and palpitations. The venom of the bushmaster snake (Lachesis) normalizes both somatic and psycho-emotional manifestations of menopause. The optimal time to start treatment with Climactoplan N is premenopause, when the severity of hormonal changes is not yet so drastic. Timely initiation of pharmacotherapy will alleviate the symptoms of menopause during menopause and avoid the need to prescribe hormonal drugs. If, according to indications, hormone therapy is necessary, then the use of Climactoplan N will also not be superfluous: in this case, the required doses of hormones will be lower, and the period of their administration will be shorter. After cessation of hormone therapy, Klimaktoplan N consolidates and stabilizes the achieved effect. As comparative clinical studies have shown, this drug is a more effective treatment for pathological menopause compared to other homeopathic remedies with similar effects (climaxan, remens, etc.).
Klimaktoplan N is available in the form of lozenges. The drug should be taken 1-2 tablets 3 times a day 30 minutes before or after meals. The duration of the medication course is determined by the doctor: on average it is 3-4 months. In agreement with the doctor, a repeat course may be carried out. When using homeopathic medicines, a temporary deterioration in the condition is sometimes observed, requiring suspension of pharmacotherapy and consultation with a doctor.
Indications for use
It is used as a monotherapy drug and in the complex treatment of menopausal syndrome with:
- tides;
- increased sweating;
- itching;
- nervous tension;
- depressive states;
- anxiety;
- heartbeat;
- dizziness;
- insomnia.
The drug Klimaktoplan is not intended for replacement therapy.
Analogues of the drug
Level 4 ATC code matches:
Floragin
Agnucaston
Bioselac
Cyclodinone
Trioginal
Qi-Klim
Saguenite
Gynekohel
Mastodinon
Mamoklam
Tazalok
Gynoflor E
Klimadinon
Klimadinon Uno
Klimalanin
The homeopathic remedy is unique in its range of active ingredients. Klimaktoplan has no structural analogues for the main active ingredients.
Analogs for pharmacological effect (for the treatment of menopausal and menopausal conditions): Abyufen , Soifem , Sagenit , Klimadinon , Klimaksan homeopathic , Klimodien ; Remens , Femoston ; Estrogel and a number of others.
Klimaktoplan K tablets No. 20*5
Name
Klimaktoplan K.
Description
Klimaktoplan K is a homeopathic medicine without approved therapeutic indications. Traditionally used in complex therapy for menopausal disorders.
Main active ingredient
Homeopathic remedy.
Release form
pills.
Dosage
100 pieces.
Indications for use
The scope of use of the drug is determined by the homeopathic properties of this drug. This includes menopausal symptoms such as hot flashes, sweating, rapid heartbeat, anxiety, and sleep disturbances.
Directions for use and doses
Unless otherwise indicated, Klimaktoplan K is used as follows: at the beginning of treatment, 1 tablet 3 times a day; after improvement occurs, the frequency of taking the drug is reduced. The tablets should be taken half an hour before or half an hour after meals, allowing them to dissolve slowly in the mouth. Homeopathic medicines should not be taken for a long period without consulting a doctor.
Use during pregnancy and lactation
The drug is not intended for use during pregnancy and lactation, therefore it is not recommended to use the drug during pregnancy and lactation.
Contraindications
It is not recommended to use the drug if you have known hypersensitivity to one of its ingredients. Caution for patients with lactose intolerance and celiac disease: Klimaktoplan K contains lactose and wheat starch. If symptoms persist or are unclear, or if new symptoms appear, you should consult a doctor, as there may be diseases that require medical attention. Interactions with other drugs are unknown.
Compound
1 tablet (250 mg) contains: active substances: Ignatia (chilibuha ignatia) D3 25 mg, Cimicifuga (black cohosh) D2 25 mg, Sepia (cuttlefish) D2 25 mg, Sanguinaria (Canadian sanguinaria) D6 25 mg; excipients: lactose monohydrate, wheat starch, magnesium stearate.
Overdose
The harmful effects of an overdose are not yet known; when taking the drug in more than the indicated doses, you should consult your doctor.
Side effect
Like any medicine, Klimaktoplan K can cause side effects, but not everyone gets them. In some cases, hypersensitivity reactions to the ingredients of the drug may occur, nosebleeds may occur, and menstrual bleeding may recur or become more frequent. In such cases, you should stop taking the drug and consult your doctor. Wheat starch, which is contained in the drug, can cause hypersensitivity reactions. General note: when taking homeopathic medicines, there may be a transient increase in existing symptoms of the disease (initial worsening); in this case, you should stop taking the drug and consult your doctor. Please tell your doctor if any of the side effects get worse or if you notice any side effect not listed in this leaflet.
Storage conditions
Store in original packaging at a temperature of 15 to 25 °C in a place protected from moisture. Keep out of the reach of children!
Buy Klimaktoplan K tablet in blister. in pack No. 20*5 in the pharmacy
Price for Klimaktoplan To the table in the sheet. in pack №20*5
Instructions for use for Klimaktoplan To the table in the sheet. in pack №20*5
Reviews about Klimaktoplan and Klimaktoplan N
Reviews from women
Analyzing the reviews of patients on the Internet, the following conclusions can be drawn: most of them note the positive effects of the drug - a decrease in the intensity of hot flashes, a decrease in irritability, improved night sleep, and a decrease in heart rate. However, some women complain of a lack of effect, many of them note an unstable or short-term effect (improvement is observed at first, but after a while the symptoms resume). There are often complaints about the disappearance of hot flashes, but the appearance of tachycardia , which forces a change in the drug. There are quite a lot of complaints about weight gain in the range of 3-5 kg.
Reviews from doctors about Klimaktoplan and Klimaktoplan N
According to gynecologists, the drug has an effect in most patients already in the first month of taking it. But, in practice, many patients violate the instructions for using the drug, which reduces the effect.
Klimaktoplan price, where to buy
The price in Moscow pharmacies varies between 350 – 445 rubles/pack, in Ukraine in Kyiv pharmacies – 89 – 115 hryvnia/pack. The price of Klimaktoplan N is within the same limits.
- Online pharmacies in RussiaRussia
- Online pharmacies in UkraineUkraine
- Online pharmacies in KazakhstanKazakhstan
ZdravCity
- Klimaktoplan N tablets 100 pcs. Dr. Wilmar Schwabe/Deutsche Homeopathy-Union DHU-Artsnaimittel
629 rub. order
Pharmacy Dialogue
- Klimaktoplan N (tab. No. 100)Deutsche Homoeopathie-Union
RUR 663 order
show more
Pharmacy24
- Klimaktoplan No. 100 tablets Dr. Wilmar Schwabe GmbH & Co.
KG, Niemecchina/Deutsche Homeopathy-Union DHU-Arznaimittel GmbH & Co. KG. No 168 UAH. order
PaniPharmacy
- Klimaktoplan tablets Klimaktoplan tablets. No. 100 Germany, DHU
170 UAH order
show more
